<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1536">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365439</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00895</org_study_id>
    <nct_id>NCT04365439</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma for COVID-19</brief_title>
  <official_title>Convalescent Plasma for the Treatment of Moderate-severe COVID-19: A Proof-of-principle Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enos Bernasconi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ente Ospedaliero Cantonale, Bellinzona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to
      patients with moderate to severe COVID-19 and assess:

        -  the titer of anti-COVID-19 antibodies in the donors and in the patients before and after
           treatment;

        -  the in-depth analysis of immunological parameters in the donors and in recipient before
           and after treatment;

        -  the impact of plasma transfusion on the reduction of viral load and inflammation

        -  safety and tolerability

        -  clinical efficacy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 27, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors</measure>
    <time_frame>At plasma donation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma</measure>
    <time_frame>Change from baseline at day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1)</measure>
    <time_frame>Change from baseline at day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs</measure>
    <time_frame>Change from day of diagnosis at day 1</time_frame>
    <description>Semiquantitative measure of viral load by rtPCR for SARS-CoV-2 by nasopharyngeal swabs, at diagnosis and on day 1,3,7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with improvement in the 7-points Ordinal Scale</measure>
    <time_frame>At day 7</time_frame>
    <description>7-point ordinal scale measure on day 0 (Baseline), day 1, 3 and 7 after plasma transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse events, severity of adverse events</measure>
    <time_frame>At day 21</time_frame>
    <description>AE will be assessed by the DAIDS scale on day 1, 3, 7 and 21. Relatedness with plasma transfusion will also be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Blood Plasma Therapy</condition>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Convalescent plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Convalescent plasma from patients after COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood plasma</intervention_name>
    <description>Convalescent plasma after COVID-19</description>
    <arm_group_label>Convalescent plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized adult patients 18 - 75 y.o. with confirmed COVID-19 infection by
             nasopharyngeal swab;

          -  radiologically confirmed pneumonia;

          -  SpO2 &gt; 92o/o and &lt; 96% (room air);

          -  ongoing thromboembolic prophylaxis.

        Exclusion Criteria:

          -  Participation to another COVID-19 trial;

          -  severe COVID-19 disease (SpO2 &lt; 93o/o in room air);

          -  severe allergic transfusion reactions or anaphylaxis in the patient history;

          -  documented lgA deficiency;

          -  unstable heart disease with signs of circulatory overload;

          -  malignancies or other concomitant diseases with poor short-term prognosis;

          -  pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Fontana, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servizio Trasfusionale, Lugano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enos Bernasconi, M.D.</last_name>
    <phone>+41 91 811 60 22</phone>
    <email>enos.bernasconi@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatrice Bernasconi</last_name>
    <phone>+41 91 811 60 21</phone>
    <email>beatrice.bernasconi@eoc.ch</email>
  </overall_contact_backup>
  <reference>
    <citation>Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.</citation>
    <PMID>32219428</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 18, 2020</study_first_submitted>
  <study_first_submitted_qc>April 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ente Ospedaliero Cantonale, Bellinzona</investigator_affiliation>
    <investigator_full_name>Enos Bernasconi</investigator_full_name>
    <investigator_title>Prof Dr med</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

